Johnson & Johnson's bridging its $2B patent cliff gap, with help from Stelara, Darzalex

15th October 2019 Uncategorised 0

Johnson & Johnson is dealing with a multibillion-dollar hit this year as generics and biosimilars eat away at prescription drug sales. That’s the bad news. The good? Its newer meds continue to deliver enough oomph to push pharma growth, which rang in at 6.4% this quarter, easily outpacing J&J’s other businesses.

More: Johnson & Johnson's bridging its B patent cliff gap, with help from Stelara, Darzalex
Source: fierce